Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group

11. Eye - guidance

To access BNF Formulary section click on the link under BNF Section/s

To access the Guidance Document click on the highlighted text under the Title column

Use documents past their review date with Caution

BNF Section/s Title Issuing Body  Date of Issue Update Due
11.6 HCD Aflibercept (Eylea®)
ICB commissioned - approval via Blueteq 
High-Cost Drugs    
11.6 HCD Brolucizumab
ICB commissioned - approval via Blueteq 
High-Cost Drugs    
11.6 HCD Brolucizumab for treating diabetic macular oedema TA820 NICE  Aug 2022  
11.6 HCD Dexamethasone intravitreal implant (Ozurdex)
ICB commissioned - approval via Blueteq 
High-Cost Drugs    
11.6 HCD Dexamethasone intravitreal implant for treating diabetic macular oedema TA824 NICE  Sep 2022  
11.2 Dry Eyes  - Kent and Medway Dry Eye Guidance
Kent and Medway ICB Feb 2024 Feb 2026
11.6 HCD Faricimab
ICB commissioned - approval via Blueteq 
High-Cost Drugs    
11.6 HCD Faricimab for treating diabetic macular oedema
TA799
NICE  Jun 2022  
11.6 HCD Faricimab for treating wet age-related macular degeneration TA800  NICE  Jun 2022  
11.6 HCD Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion TA1004 NICE Sep2024  
11.6 HCD Fluocinolone acetonide(Iluvien®)
ICB commissioned - approval via Blueteq 
High-Cost Drugs    
11.6 HCD Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema NICE Guidance TA953 NICE Mar 2024 -
11.6 HCD Ranibizumab Biosimilar (Ongavir)
ICB commissioned - approval via Blueteq
High-Cost Drugs    
11.6 HCD Ranibizumab and pegaptanib for the treatment of age-related macular degeneration TA155 NICE  May 2012  
11.6 HCD Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion  TA283  NICE  May 2013  
11.6 HCD Ranibizumab for treating diabetic macular oedema  TA274  NICE  Feb 2013  
11.6 HCD Ranibizumab for treating choroidal neovascularisation associated with pathological myopia TA298  NICE  Nov 2013  
  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •